{Reference Type}: Journal Article
{Title}: Stability of Protein Pharmaceuticals: Recent Advances.
{Author}: Manning MC;Holcomb RE;Payne RW;Stillahn JM;Connolly BD;Katayama DS;Liu H;Matsuura JE;Murphy BM;Henry CS;Crommelin DJA;
{Journal}: Pharm Res
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 27
{Factor}: 4.58
{DOI}: 10.1007/s11095-024-03726-x
{Abstract}: There have been significant advances in the formulation and stabilization of proteins in the liquid state over the past years since our previous review. Our mechanistic understanding of protein-excipient interactions has increased, allowing one to develop formulations in a more rational fashion. The field has moved towards more complex and challenging formulations, such as high concentration formulations to allow for subcutaneous administration and co-formulation. While much of the published work has focused on mAbs, the principles appear to apply to any therapeutic protein, although mAbs clearly have some distinctive features. In this review, we first discuss chemical degradation reactions. This is followed by a section on physical instability issues. Then, more specific topics are addressed: instability induced by interactions with interfaces, predictive methods for physical stability and interplay between chemical and physical instability. The final parts are devoted to discussions how all the above impacts (co-)formulation strategies, in particular for high protein concentration solutions.'